{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:15:05Z","timestamp":1792289705636,"version":"4.4.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare congenital arrhythmogenic disorder induced by physical or emotional stress. It mainly affects children and younger adults and is characterized by rapid polymorphic and bidirectional ventricular tachycardia. Symptoms can include dizziness, palpitations, and presyncope, which may progress to syncope, hypotonia, convulsive movements, and sudden cardiac death. CPVT is the result of perturbations in Ca<jats:sup>2+<\/jats:sup> ion handling in the sarcoplasmic reticulum of cardiac myocytes. Mutations in the cardiac ryanodine receptor gene and the calsequestrin isoform 2 gene are most commonly seen in familial CPVT patients. Under catecholaminergic stimulation, either mutation can result in an excess Ca<jats:sup>2+<\/jats:sup> load during diastole resulting in delayed after depolarization and subsequent arrhythmogenesis. The current first-line treatment for CPVT is \u03b2-blocker therapy. Other therapeutic interventions that can be used in conjunction with \u03b2-blockers include moderate exercise training, flecainide, left cardiac sympathetic denervation, and implantable cardioverter-defibrillators. Several potential therapeutic interventions, including verapamil, dantrolene, JTV519, and gene therapy, are also discussed.<\/jats:p>","DOI":"10.1097\/crd.0000000000000302","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T09:30:13Z","timestamp":1578994213000},"page":"325-331","source":"Crossref","is-referenced-by-count":37,"title":["Catecholaminergic Polymorphic Ventricular Tachycardia"],"prefix":"10.1097","volume":"28","author":[{"given":"Chan W.","family":"Kim","sequence":"first","affiliation":[{"name":"From the Cardiology Division, Department of Medicine, NY Medical College and Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"From the Cardiology Division, Department of Medicine, NY Medical College and Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Dutta","sequence":"additional","affiliation":[{"name":"From the Cardiology Division, Department of Medicine, NY Medical College and Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Frenkel","sequence":"additional","affiliation":[{"name":"From the Cardiology Division, Department of Medicine, NY Medical College and Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"From the Cardiology Division, Department of Medicine, NY Medical College and Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.108.829267","article-title":"Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.","volume":"119","author":"Hayashi","year":"2009","journal-title":"Circulation"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.CIR.0000020013.73106.D8","article-title":"Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.","volume":"106","author":"Priori","year":"2002","journal-title":"Circulation"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0033-0620(98)80020-0","article-title":"Polymorphic ventricular tachyarrhythmias in the absence of organic heart disease: classification, differential diagnosis, and implications for therapy.","volume":"41","author":"Viskin","year":"1998","journal-title":"Prog Cardiovasc Dis"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/01.CIR.91.5.1512","article-title":"Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients.","volume":"91","author":"Leenhardt","year":"1995","journal-title":"Circulation"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00059-007-2975-2","article-title":"Catecholaminergic polymorphic ventricular tachycardia.","volume":"32","author":"Liu","year":"2007","journal-title":"Herz"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1540-8167.2011.02138.x","article-title":"A classic electrocardiographic manifestation of catecholaminergic polymorphic ventricular tachycardia.","volume":"23","author":"Richter","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/heart.89.1.66","article-title":"Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death.","volume":"89","author":"Sumitomo","year":"2003","journal-title":"Heart"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/CIRCRESAHA.110.226845","article-title":"Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis.","volume":"108","author":"Priori","year":"2011","journal-title":"Circ Res"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCULATIONAHA.119.039711","article-title":"Insights into the pathogenesis of catecholaminergic polymorphic ventricular tachycardia from engineered human heart tissue.","volume":"140","author":"Park","year":"2019","journal-title":"Circulation"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrcardio.2012.93","article-title":"Inherited calcium channelopathies in the pathophysiology of arrhythmias.","volume":"9","author":"Venetucci","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.yjmcc.2009.10.016","article-title":"Beta-adrenergic receptor signaling in the heart: role of CaMKII.","volume":"48","author":"Grimm","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1161\/CIRCRESAHA.116.304030","article-title":"Genetics of sudden cardiac death.","volume":"116","author":"Bezzina","year":"2015","journal-title":"Circ Res"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/hmg\/dds104","article-title":"Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human.","volume":"21","author":"Roux-Buisson","year":"2012","journal-title":"Hum Mol Genet"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ajhg.2012.08.015","article-title":"Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death.","volume":"91","author":"Nyegaard","year":"2012","journal-title":"Am J Hum Genet"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1086\/324565","article-title":"A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel.","volume":"69","author":"Lahat","year":"2001","journal-title":"Am J Hum Genet"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1161\/01.RES.0000192146.85173.4b","article-title":"Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death.","volume":"97","author":"Jiang","year":"2005","journal-title":"Circ Res"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/01.RES.0000091335.07574.86","article-title":"Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes.","volume":"93","author":"George","year":"2003","journal-title":"Circ Res"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"13062","DOI":"10.1073\/pnas.0402388101","article-title":"RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR).","volume":"101","author":"Jiang","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1161\/CIRCULATIONAHA.111.023259","article-title":"Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca2+release leading to catecholaminergic polymorphic ventricular tachycardia.","volume":"124","author":"Suetomi","year":"2011","journal-title":"Circulation"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1085\/jgp.200709907","article-title":"Luminal Ca2+ regulation of single cardiac ryanodine receptors: insights provided by calsequestrin and its mutants.","volume":"131","author":"Qin","year":"2008","journal-title":"J Gen Physiol"},{"issue":"pt 13","key":"R21-20230903","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1113\/jphysiol.2009.172049","article-title":"Cardiac calsequestrin: quest inside the SR.","volume":"587","author":"Gy\u00f6rke","year":"2009","journal-title":"J Physiol"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1172\/JCI31080","article-title":"Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia.","volume":"117","author":"Song","year":"2007","journal-title":"J Clin Invest"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1161\/01.RES.0000038886.18992.6B","article-title":"Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia.","volume":"91","author":"Postma","year":"2002","journal-title":"Circ Res"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.hrthm.2013.05.014","article-title":"HRS\/EHRA\/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in june 2013.","volume":"10","author":"Priori","year":"2013","journal-title":"Heart Rhythm"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.jacc.2017.10.053","article-title":"2017 AHA\/ACC\/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jacep.2016.01.020","article-title":"Competitive sports participation in patients with catecholaminergic polymorphic ventricular tachycardia: a single center\u2019s early experience.","volume":"2","author":"Ostby","year":"2016","journal-title":"JACC Clin Electrophysiol"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1152\/japplphysiol.00818.2012","article-title":"Exercise training improves cardiac function and attenuates arrhythmia in CPVT mice.","volume":"113","author":"Kurtzwald-Josefson","year":"2012","journal-title":"J Appl Physiol (1985)"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1161\/CIRCGENETICS.110.959429","article-title":"A clinical approach to inherited arrhythmias.","volume":"5","author":"Cerrone","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/europace\/eur277","article-title":"Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments.","volume":"14","author":"van der Werf","year":"2012","journal-title":"Europace"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.hrthm.2015.09.029","article-title":"Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with \u03b21-selective \u03b2-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.","volume":"13","author":"Leren","year":"2016","journal-title":"Heart Rhythm"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/CIRCEP.114.002217","article-title":"Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.","volume":"8","author":"Roston","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/CIRCEP.112.970517","article-title":"Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives.","volume":"5","author":"van der Werf","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R33-20230903","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.hrthm.2018.06.046","article-title":"Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: a systematic review.","volume":"15","author":"Roston","year":"2018","journal-title":"Heart Rhythm"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCEP.113.000170","article-title":"Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate.","volume":"6","author":"Miyake","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1161\/CIRCRESAHA.111.247338","article-title":"Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.","volume":"109","author":"Liu","year":"2011","journal-title":"Circ Res"},{"key":"R36-20230903","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nm.1942","article-title":"Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.","volume":"15","author":"Watanabe","year":"2009","journal-title":"Nat Med"},{"key":"R37-20230903","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.jacc.2011.01.026","article-title":"Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.","volume":"57","author":"van der Werf","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R38-20230903","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.hrthm.2012.12.035","article-title":"Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.","volume":"10","author":"Watanabe","year":"2013","journal-title":"Heart Rhythm"},{"key":"R39-20230903","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamacardio.2017.1320","article-title":"Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial.","volume":"2","author":"Kannankeril","year":"2017","journal-title":"JAMA Cardiol"},{"key":"R40-20230903","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.yjmcc.2009.10.005","article-title":"Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.","volume":"48","author":"Hilliard","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"R41-20230903","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.hrthm.2009.03.024","article-title":"Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery.","volume":"6","author":"Collura","year":"2009","journal-title":"Heart Rhythm"},{"key":"R42-20230903","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/CIRCULATIONAHA.115.015731","article-title":"Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation.","volume":"131","author":"De Ferrari","year":"2015","journal-title":"Circulation"},{"key":"R43-20230903","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/CIRCEP.115.003159","article-title":"Physical and psychological consequences of left cardiac sympathetic denervation in long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia.","volume":"8","author":"Waddell-Smith","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R44-20230903","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.hrthm.2010.03.046","article-title":"Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy.","volume":"7","author":"Odero","year":"2010","journal-title":"Heart Rhythm"},{"key":"R45-20230903","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jacc.2011.09.043","article-title":"Bilateral cardiac sympathetic denervation for the management of electrical storm.","volume":"59","author":"Ajijola","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R46-20230903","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.hrthm.2013.11.028","article-title":"Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term follow-up.","volume":"11","author":"Vaseghi","year":"2014","journal-title":"Heart Rhythm"},{"key":"R47-20230903","doi-asserted-by":"crossref","first-page":"653","DOI":"10.33963\/KP.14834","article-title":"Bilateral cardiac sympathetic denervation in catecholaminergic polymorphic ventricular tachycardia.","volume":"77","author":"Stec","year":"2019","journal-title":"Kardiol Pol"},{"key":"R48-20230903","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1540-8167.2005.40516.x","article-title":"Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations.","volume":"16","author":"Swan","year":"2005","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R49-20230903","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.hrthm.2007.05.017","article-title":"Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.","volume":"4","author":"Rosso","year":"2007","journal-title":"Heart Rhythm"},{"key":"R50-20230903","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.hrthm.2010.07.004","article-title":"Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice.","volume":"7","author":"Katz","year":"2010","journal-title":"Heart Rhythm"},{"key":"R51-20230903","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jacc.2009.01.065","article-title":"Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor.","volume":"53","author":"Kobayashi","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R52-20230903","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0092-8674(03)00434-3","article-title":"FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death.","volume":"113","author":"Wehrens","year":"2003","journal-title":"Cell"},{"key":"R53-20230903","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1126\/science.1094301","article-title":"Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2.","volume":"304","author":"Wehrens","year":"2004","journal-title":"Science"},{"key":"R54-20230903","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1476-5381.2012.01995.x","article-title":"JTV519 (K201) reduces sarcoplasmic reticulum Ca2+ leak and improves diastolic function in vitro in murine and human non-failing myocardium.","volume":"167","author":"Sacherer","year":"2012","journal-title":"Br J Pharmacol"},{"key":"R55-20230903","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/01.CIR.0000044917.74408.BE","article-title":"FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure.","volume":"107","author":"Yano","year":"2003","journal-title":"Circulation"},{"key":"R56-20230903","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1042\/BJ20070135","article-title":"K201 (JTV519) suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2 irrespective of FKBP12.6 association.","volume":"404","author":"Hunt","year":"2007","journal-title":"Biochem J"},{"key":"R57-20230903","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/cvr\/cvp273","article-title":"A mechanism of ryanodine receptor modulation by FKBP12\/12.6, protein kinase A, and K201.","volume":"85","author":"Blayney","year":"2010","journal-title":"Cardiovasc Res"},{"key":"R58-20230903","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/cvr\/cvq007","article-title":"Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation.","volume":"87","author":"Sedej","year":"2010","journal-title":"Cardiovasc Res"},{"key":"R59-20230903","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1172\/JCI37649","article-title":"Role of chronic ryanodine receptor phosphorylation in heart failure and \u03b2-adrenergic receptor blockade in mice.","volume":"120","author":"Shan","year":"2010","journal-title":"J Clin Invest"},{"key":"R60-20230903","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1161\/CIRCULATIONAHA.110.982298","article-title":"Ryanodine receptor phosphorylation by calcium\/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure.","volume":"122","author":"van Oort","year":"2010","journal-title":"Circulation"},{"key":"R61-20230903","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1161\/01.RES.0000125626.33738.E2","article-title":"Ca2+\/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor.","volume":"94","author":"Wehrens","year":"2004","journal-title":"Circ Res"},{"key":"R62-20230903","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.yjmcc.2010.10.001","article-title":"Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+\/-) mice with catecholaminergic polymorphic ventricular tachycardia.","volume":"50","author":"Liu","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"R63-20230903","doi-asserted-by":"crossref","first-page":"e843","DOI":"10.1038\/cddis.2013.369","article-title":"CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia.","volume":"4","author":"Di Pasquale","year":"2013","journal-title":"Cell Death Dis"},{"key":"R64-20230903","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.118.038514","article-title":"Gene therapy for catecholaminergic polymorphic ventricular tachycardia by inhibition of Ca2+\/calmodulin-dependent kinase II.","volume":"140","author":"Bezzerides","year":"2019","journal-title":"Circulation"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:12:46Z","timestamp":1693732366000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000302","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,2]]}}}